Spots Global Cancer Trial Database for Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Official Title: A Phase I Trial of Combined Nimotuzumab With NK Cells Adoptive Transfer for the Treatment of Advanced Cancer

Study ID: NCT03554889

Conditions

Advanced Cancer

ADCC

NK Cell Mediated Immunity

Nimotuzumab

Adaptive Transfer

Interventions

NK Cell adaptive transfer

Nimotuzumab

Study Description

Brief Summary: NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. NK also express an activating Fc receptor that mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced cancer patients. Blood samples will also be collected for research purposes.

Detailed Description: This is a phase I clinical study of expanded NK cells from autologous origin. The NK cell will be selected and expanded ex vivo and infused back into patients. Nimotuzumab will be used 24 hours before infusion. 21 advanced cancer patients are planned to receive two cycles of NK cells and Nimotuzumab treatment. Biomarkers and immunological markers are collected and analyzed as well.